Effect of secondary hyperparathyroidism serum on endothelial cells and intervention with Klotho

Chen,Cheng; Mao,Huijuan; Yu,Xiangbo; Sun,Bin; Zeng,Ming; Zhao,Xiufen; Qian,Jun; Liu,Jia; Xing,Changying

doi:10.3892/mmr.2015.3606

Effect of secondary hyperparathyroidism serum on endothelial cells and intervention with Klotho

Authors:
- Cheng Chen
- Huijuan Mao
- Xiangbo Yu
- Bin Sun
- Ming Zeng
- Xiufen Zhao
- Jun Qian
- Jia Liu
- Changying Xing
View Affiliations

Affiliations: Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: April 9, 2015 https://doi.org/10.3892/mmr.2015.3606
Pages: 1983-1990

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of the serum of patients with secondary hyperparathyroidism (SHPT) on endothelial cells and to examine the protective effect and the possible mechanism of Klotho. A total of three types of mixed serum from 15 patients with SHPT scheduled for parathyroidectomy, 10 chronic kidney disease (CKD) patients at stage 5 without SHPT and 15 healthy volunteers were collected. Initially, human umbilical vein endothelial cells (HUVECs) were incubated in vitro with the three types of serum and levels of proliferation were compared by assessing viable cell numbers with cell counting kit‑8 (CCK‑8). Subsequently, HUVECs were divided into three groups: Control group (healthy serum medium), SHPT group (SHPT serum) and Klotho treatment group (SHPT serum and Klotho). The proliferative and apoptotic levels of endothelial cells were evaluated by CCK‑8 and flow cytometry, respectively. The levels of extracellular signal‑regulated kinase (ERK1/2) and phosphorylated forms of ERK1/2 (p‑ERK1/2) were detected using western blotting (with or without ERK1/2 inhibitor PD98059). The synthesis of nitric oxide (NO) was measured using the nitrate reduction method. The proliferation of HUVECs was inhibited by the serum from SHPT patients and CKD‑5 patients without SHPT and the inhibitory effects of the SHPT serum were the most marked (P<0.05). Inhibition of HUVEC proliferation by SHPT serum occurred in a concentration‑dependent manner within a specific range (5‑20%; P<0.05) and also in a time‑dependent manner within 6‑24 h. Proliferation was partly restored and apoptosis was inhibited when 50‑100 ng/ml Klotho was added into 10% SHPT serum (P<0.05). At the same time, the expression of p‑ERK1/2 was upregulated, which may be inhibited by PD98059. The synthesis of NO was decreased in the SHPT group (P<0.05) and increased following treatment with Klotho (P<0.05). The results of the present study indicated that the proliferation of HUVECs was inhibited by the serum from SHPT patients. Klotho may partly antagonize this effect due to its inhibition of HUVEC apoptosis and upregulation of p‑ERK1/2.

View Figures

View References

1	Foley RN, Parfrey PS and Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 32(5 Suppl 3): S122–S129. 1998. View Article : Google Scholar
2	Jourde-chiche N, Dou L, Cerini C, et al: Vascular incompetence in dialysis patients-protein-bound uremic toxins and endothelial dysfunction. Semin Dial. 24:327–337. 2011. View Article : Google Scholar : PubMed/NCBI
3	Van Ballegooijen AJ, Reinders I, Visser M, et al: Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. Am Heart J. 165:655–664. 2013. View Article : Google Scholar : PubMed/NCBI
4	Kuro-o M, Matsumura Y, Aizawa H, et al: Mutation of the mouse klotho gene leads to a syndrome resembling aging. Nature. 3909:45–51. 1997. View Article : Google Scholar
5	Kamemori M, Ohyama Y, Kurabayashi M, et al: Expression of klotho protein in the inner ear. Hear Res. 171:103–110. 2002. View Article : Google Scholar : PubMed/NCBI
6	Nagai T, Yamada K, Kim HC, et al: Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J. 17:50–52. 2003.
7	Anamizu Y, kawaguchi H, Seichi A, et al: Klotho insufficiency causes decrease of ribosomal RNA gene transcription activity, cytoplasmic RNA and rough ER in the spinal anterior horn cells. Acta Neuropathol. 109:457–466. 2005. View Article : Google Scholar : PubMed/NCBI
8	Hu MC, Shi M, Zhang J, et al: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 22:124–136. 2011. View Article : Google Scholar :
9	Rakugi H, Matsukawa N, Ishikawa K, et al: Anti-oxidative effect of klotho on endothelial cells through cAMP activation. Endocrine. 31:82–87. 2007. View Article : Google Scholar : PubMed/NCBI
10	Carracedo J, Buendia P, Merino A, et al: klotho modulates the stress response in human senescent endothelial cells. Mech Ageing Dev. 133:647–654. 2012. View Article : Google Scholar : PubMed/NCBI
11	Yang K, Nie L, Huang Y, et al: Ameliration of uremic toxin indoxyl sulfate-induced endothelial cell dysfunction by klotho protein. Toxicol Lett. 215:77–83. 2012. View Article : Google Scholar : PubMed/NCBI
12	Komaba H and Fukagawa M: FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 77:292–298. 2010. View Article : Google Scholar
13	Linder A, Charra B and Sherrard DJ: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Eng J Med. 290:697–701. 1974. View Article : Google Scholar
14	Eberhardt RT, Forgione MA, Cap A, et al: Endothelial dysfunc dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 106:483–491. 2000. View Article : Google Scholar : PubMed/NCBI
15	Raff AC, Meyer TW and Hostetter TH: New insights into uremic toxicity. Curr Opin Nephrol Hypertens. 17:560–565. 2008. View Article : Google Scholar : PubMed/NCBI
16	Bhuriva R, Li S, Chen SC, et al: Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program. Am J Kidney Dis. 5(Suppl 4): 3–10. 2009. View Article : Google Scholar
17	de Groot K, Bahlmann FH, Sowa J, et al: Uremia causes endo-thelial progenitor cell deficiency. Kidney Int. 66:641–646. 2004. View Article : Google Scholar : PubMed/NCBI
18	Choi JH, Kim KL, Huh W, et al: Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 24:1246–1252. 2004. View Article : Google Scholar : PubMed/NCBI
19	Carmeliet P, Moons L, Stassen JM, et al: Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Patho. 150:761–776. 1997.
20	Goligorsky MS, Yasuda K and Ratliff B: Dysfunctional endothelial progenitor cells in chronic kidney disease. J Am Soc Nephrol. 21:911–919. 2010. View Article : Google Scholar : PubMed/NCBI
21	Matsumura Y, Aizawa H, Nakamura T, et al: Identification of the human klotho gene and its two transcripts encoding membrance and secreted klotho protein. Biochem Biophys Res Commun. 242:626–630. 1998. View Article : Google Scholar : PubMed/NCBI
22	Shiraki-lida T, Aizawa H, Matsumura Y, et al: Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett. 424:6–10. 1998.
23	Tohyma O, Imura A, Iwano A, et al: Klotho is novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronidase. J Biol Chem. 279:9777–9784. 2004. View Article : Google Scholar
24	Kachiwala SJ, Harris SE, Wright AF, et al: Genetic influences on oxidative stress and their association with normal cognitive aging. Neurosci Lett. 386:116–120. 2005. View Article : Google Scholar : PubMed/NCBI
25	Yamamoto M, Clark JD, Pastor JV, et al: Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem. 280:38029–38034. 2005. View Article : Google Scholar : PubMed/NCBI
26	Jie YU, Deng M, Zhao J, et al: Decreased expression of klotho gene in uremic atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 391:261–266. 2010. View Article : Google Scholar
27	Kooman JP, Broers NJ, Uswat L, et al: Out of control: accelerated aging in uremia. Nephrol Dial Transplant. 28:48–54. 2013. View Article : Google Scholar
28	Zou MH, Shi C and Cohen RA: Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest. 109:817–826. 2002. View Article : Google Scholar : PubMed/NCBI
29	Moncada S and Higgs EA: Nitric oxide and the vascular endothelium. Handb Exp Pharmacol. 176(Pt 1): 213–254. 2006.PubMed/NCBI
30	Lubos E, Handy DE and Loscalzo J: Role of oxidative stress and nitric oxide in atherothrombosis. Front Biosci. 13:5323–5344. 2008. View Article : Google Scholar : PubMed/NCBI
31	Lawrence MC, Jivan A, Shao C, et al: The roles of MAPKs in disease. Cell Res. 18:436–442. 2008. View Article : Google Scholar : PubMed/NCBI
32	Cross TG, Scheel-Toellner D, Henriquez NV, et al: Serine/threonine protein kinases and apoptosis. Exp Cell Res. 256:34–41. 2000. View Article : Google Scholar : PubMed/NCBI
33	Pearson G, Robinson F, Beers Gibson T, et al: Mitogenactivated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 22:153–183. 2001.PubMed/NCBI
34	Cobb MH: MAP kinase pathways. Prog Biophys Mol Biol. 71:479–500. 1999. View Article : Google Scholar : PubMed/NCBI
35	Xia Z, Dickens M, Raingeaud J, et al: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
36	Steelman LS, Bertrand FE and McCubrey JA: The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets. 8:537–550. 2004. View Article : Google Scholar : PubMed/NCBI
37	Steelman LS, Pohnert SC, Shelton JG, et al: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 18:189–218. 2004. View Article : Google Scholar : PubMed/NCBI